Icon has reached a preliminary agreement with Intel to use the Intel Pharma Analytics Platform in clinical trials. Launched in 2013, the Intel platform can continuously monitor and collect clinical ...

DUBLIN, Ireland--(BUSINESS WIRE)--The Tánaiste and Minister for Enterprise, Trade and Employment, Leo Varadkar TD announced today that ICON plc (NASDAQ: ICLR), a Dublin-based global provider of drug ...

DUBLIN, December 02, 2025--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced results of its latest industry survey, examining the challenges ...

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced the expansion of its portfolio of artificial ...

Icon ($ICLR) and Medidata ($MDSO) have teamed up to combine their patient-reported outcome (PRO) capabilities. Medidata is providing the underlying technology, while ...

The consolidation brings together two organizations with a history of robust growth and performance ready to build on this strength using the outstanding talent of both companies to deliver enhanced ...

Contract research firm Icon is preparing to ramp up the use of analytics and wearable technologies to increase the appeal of clinical trials as a care option and to boost efficiency of its operations.

ICON has agreed to acquire PRA Health Sciences for approximately $12 billion in cash and stock, the companies said, in a deal that continues the consolidation of contract research organizations (CROs) ...

DUBLIN--(BUSINESS WIRE)-- ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research ...

(Reuters) - Icon Plc said on Wednesday it will buy rival PRA Health Sciences Inc in a deal valued at about $12 billion, to create a contract drug research firm that can tap into the growing demand for ...